Answers from the Lab

Mayo Clinic Laboratories

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.

  1. Lab Outreach Delivers Value, Growth, and Strategic Advantage

    20h ago

    Lab Outreach Delivers Value, Growth, and Strategic Advantage

    In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss recent artificial intelligence (AI) initiatives in the news. She then welcomes Jane Hermansen, manager of Mayo Clinic Laboratories’ Outreach Program, to discuss the value of outreach programs in strengthening laboratories and supporting broader healthcare systems. AI’s potential and limitations (00:01): Learn what’s next and the challenges that remain as Drs. Pritt and Morice discuss recent stories about AI in healthcare. Value of outreach (07:30): Discover how laboratory outreach programs support their organizations, delivering benefits that range from improved patient care to lower testing costs and growth across health system service lines.Getting the most from outreach (15:54): Learn the three most important things lab leaders can do to get the greatest value from their outreach program. The future of outreach (17:53): Get insights on how outreach may evolve in the coming years as healthcare changes.Resources Fortune: A decade after the ‘Godfather of AI’ said radiologists are obsolete, salaries are $571K and growing“Answers From the Lab” podcast: Digital Advances: What's Next for Clinical Diagnostics?Personalized pathways through digital diagnostics: A Q&A with Chris Garcia, M.D. Outreach & Business SolutionsOwn your lab: Hospital-owned labs generate long-term financial and clinical valueLeveraging the Laboratory Conference

    23 min
  2. How Pharmacogenomics Deliver More Precise Cancer Therapy

    Jun 11

    How Pharmacogenomics Deliver More Precise Cancer Therapy

    In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to discuss updates on the Protecting Access to Medicare Act (PAMA) and other policy changes affecting clinical diagnostics. Later, Dr. Pritt welcomes Ann Moyer, M.D., Ph.D., a molecular genetic pathologist at Mayo Clinic and chair of the hereditary genetics practice, to explore how precision therapeutics are improving cancer treatments. PAMA update (00:01): Get the latest on PAMA as the first data collection period begins, including ongoing efforts to advance the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act.Policy changes influencing diagnostics (04:09): Learn how evolving reimbursement policies for blood-based cancer screening and a proposed CLIA modernization bill may impact the field.Pharmacogenomic tests improving cancer care (08:14): Discover how pharmacogenomics are benefiting patients with cancer, the benefits of medication-based testing, and how this field is advancing.Resources CMS: CLFS & PAMA reporting and resourcesPrecision Oncology Therapeutics: Personalized cancer treatmentAnswers From the Lab: Genetic Tests Identify Risk of Irinotecan-Induced Toxicity: John Logan Black, M.D.Answers From the Lab: Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

    21 min
  3. Risks Increase as Ticks, Mosquitoes, and Similar Vectors Spread

    May 28

    Risks Increase as Ticks, Mosquitoes, and Similar Vectors Spread

    In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, speaks with William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, about Ebola, hantavirus and takeaways from a recent healthcare conference. Later, she welcomes Elli Theel, Ph.D., a microbiologist in Mayo Clinic’s Department of Laboratory Medicine and Pathology, to explore vector-borne diseases. Top industry topics (00:04): Dr. Morice highlights key topics from a recent major healthcare conference, including AI and payment reform.Infectious diseases in the news (04:04): Overview of hantavirus, Ebola, and why laboratory medicine is important during outbreaks. Growing prevalence of vector-borne diseases (06:48): Insights on the growing prevalence of vector-borne diseases.Testing options (09:45): Understand the different types of testing available for pathogens and when it is best to use each one. Innovation and discovery (17:05): Discover emerging pathogens and advances in detection.Protect yourself (19:41): Learn easy ways to protect yourself and your family from vector-borne diseases.  Note: Information in this post was accurate at the time of its posting. Resources Forbes: Is hantavirus an emerging threat? What you need to knowVector-borne diseases by geographic regionVector-borne diseases: The right tests for detection and diagnosisLearn the ABCs of ticks

    23 min
  4. Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes

    Mar 19

    Preeclampsia Test Helps Extend Pregnancy to Improve Outcomes

    In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to share industry updates and Mayo Clinic’s test development success in 2025. Later, Dr. Pritt welcomes Janelle Santos, M.D., a maternal-fetal medicine specialist at Mayo Clinic, to discuss how she uses a preeclampsia test to care for her patients. Public policy insights for 2026 (00:34): Dr. Bill Morice shares insights on reimbursement and AI-related policy developments following an association meeting in Washington, D.C. An unprecedented year for test development (04:45): Discover how Mayo Clinic’s record year for test development delivers value to Mayo Clinic’s patients and Mayo Clinic Laboratories’ clients.Novel preeclampsia testing (08:13): Learn how new clinical testing helps physicians improve outcomes for women at risk for preeclampsia and their babies. Note: Information in this post was accurate at the time of its posting. Resources 4 steps to establishing a new approach to innovation Innovation beyond the bench: Translating science into better diagnostics and outcomesPreeclampsia: Empowering confident decision-making through preeclampsia risk assessmentAssay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. Preeclampsia sFlt-1/PIGF Ratio, Serum (Mayo ID: PERA)

    18 min

Ratings & Reviews

5
out of 5
21 Ratings

About

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.

You Might Also Like